ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PRLD vs TTRX // EV/EBITDA & P/E VALUATION

Prelude Therapeutics Incorporated (NASDAQ) VS. Turn Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PRLD 2 — TTRX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRLD VS. TTRX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PRLD TTRX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.30% -6.70 TTRX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -17.23% -0.78% -16.45 TTRX /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 73.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 1/9 +3.00 PRLD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.1 43.4 +5.73 PRLD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $327.2M $327.3M -$116.3K TTRX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PRLD REV TTRX REV PRLD GROSS % TTRX GROSS % PRLD FCF TTRX FCF
FY 2025 $12.1M $0 — — -$56.4M -$2.6M
FY 2024 $7.0M $0 — — -$103.7M -$1.4M
FY 2023 $0 — — — -$107.1M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRLD // BETA —
TTRX // BETA —